Method of obtaining particles of microcapsulated antiseptic dorogov's stimulator (ads) 2 fraction in xanthan gum, possessing supramolecular properties

FIELD: chemistry.

SUBSTANCE: method represents physico-chemical of precipitation with non-solvent, in which as microcapsule envelope xanthan gum, as core - ADS 2 fraction, and as precipitating agent - benzene are used.

EFFECT: simplification and acceleration of the process of obtaining microcapsules and increase of output by their weight.

3 dwg, 3 ex

 

The invention relates to the field of encapsulation.

Previously known methods for producing microcapsules.

In Pat. 2173140, IPC A61K 009/50, A61K 009/127, Russian Federation, publ. 10.09.2001, method for obtaining kremnijorganicheskih microcapsules using a rotary cavitation plants with high shear effort and powerful acoustic phenomena of sound and ultrasound range for dispersion.

The disadvantage of this method is the use of special equipment - rotary-cavity setup, which has the ultrasonic action that affects the formation of microcapsules and can cause adverse reactions due to the fact that ultrasound destructive effect on the polymers of protein nature, therefore the proposed method is applicable when working with polymers of synthetic origin.

In Pat. 2359662 IPC A61K 009/56, A61J 003/07, B01J 013/02, A23L 001/00 publ. 27.06.2009, Russian Federation, proposed a method of producing microcapsules of sodium chloride with the use of spray cooling in the spray tower Niro under the following conditions: air temperature at the inlet 10°C, the temperature at the outlet 28°C, the speed of rotation of the spray drum 10000 rpm/min Microcapsules according to the invention have improved stability and provide regulation which has been created and/or prolonged release of the active ingredient.

Disadvantages of the proposed method are the duration of the process and the use of special equipment, a set of conditions (temperature of inlet air 10°C, the temperature at the outlet 28°C, the speed of rotation of the spray drum 10000 rpm).

The closest method is the method proposed in U.S. Pat. 2134967, IPC A01N 53/00, A01N 25/28, publ.27.08.1999, the Russian Federation, is dispersed In water solution mixture of natural lipids and a PYRETHROID insecticide in the weight ratio of 2-4:1 in an organic solvent, which leads to simplification of the method of microencapsulation.

The disadvantage of this method is the dispersion in the aquatic environment, which makes the proposed method applicable to the production of microcapsules of water-soluble drugs in water-soluble polymers.

The technical objective is the simplification and acceleration of the process of production of microcapsules, the reduction of losses upon receipt of the microcapsules (increase in mass).

The solution of the technical problem is achieved by a method of producing particles encapsulated activator-promoter Dorogov (DCA) 2 fraction, characterized in that as the shell of the microcapsules is used xanthan gum, and as the core - SDA 2 faction when receiving the encapsulated particles by precipitation with nerastvorim using benzene as osdial is, the process of production of microcapsules is carried out without special equipment.

A distinctive feature of the proposed method is to obtain microcapsules by precipitation with nerastvorim using benzene as a precipitator, and the use of xanthan gum as a shell particles and the SDA 2 fraction as a kernel.

The result of the proposed method are obtaining microcapsules SDA 2 fraction in the shell xanthan gum.

SDA 2 fraction is a fabric preparation of animal origin. Comprises: connection active sulfhydryl group, derivatives of aliphatic amines, carboxylic acids, aliphatic and cyclic hydrocarbons, derivatives of amides and water. The SDA-2 in oral application has an activating effect on the Central nervous system and autonomic nervous system, stimulates motor activity of the gastrointestinal tract, the secretion of digestive glands, increases the activity of the digestive and tissue enzymes, improves the penetration of the ions Na+ and K+ across cell membranes, helps normalize digestion, nutrient absorption and increase the natural resistance of the organism. When applied externally, the drug stimulates the activity of the reticuloendothelial system, normalizes tro is the IR and accelerates regeneration of damaged tissues, has a strong antiseptic and anti-inflammatory action.

In Fig.1 self-organization of nano-capsular SDA 2 fraction in xanthan gum at a concentration of 0.5% by: (a) increase in 505 times, b) with increase in 930 times) with the increase in 1770 times.

In Fig.2 self-organization of nano-capsular SDA 2 fraction in xanthan gum at a concentration of 0.25% by: (a) increase in 505 times, b) with increase in 930 times.

In Fig.3 self-organization of nano-capsular SDA 2 fraction in xanthan gum at a concentration of 0.125 per cent: (a) increase in 505 times, b) with increase in 930 times.

EXAMPLE 1 Obtaining microcapsules SDA 2 fraction in xanthan gum

100 mg SDA 2 fraction was dispersed in a solution of xanthan gum in butanol containing the specified 300 mg of the polymer in the presence of 0.01 g of the drug Is (ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid, and citric acid, as Tihonova may be etherification other glycerides and as oxanilate - other fatty acids. Free acid groups can be neutralized with sodium) under stirring 1300 Rev/sec. Then poured 5 ml of benzene and 1 ml of water. The resulting suspension is filtered and dried at room temperature.

Received 0,396 g of powder of microcapsules. The yield was 99%.

USE the 2 Obtaining microcapsules SDA 2 fraction in xanthan gum

100 mg SDA 2 fraction was dispersed in a solution of xanthan gum in butanol containing the specified 100 mg of the polymer in the presence of 0.01 g of the drug Is (ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid, and citric acid, as Tihonova may be etherification other glycerides and as oxanilate - other fatty acids. Free acid groups can be neutralized with sodium) under stirring 1300 Rev/sec. Then poured 5 ml of benzene and 1 ml of water. The resulting suspension is filtered and dried at room temperature.

Received 0,188 g of powder of microcapsules. The yield was 94%.

EXAMPLE 3 Study of self-organization of the particles from solutions

From a powder of microcapsules obtained by the method described in example 1, there were prepared aqueous solutions of concentrations 1%, 0,5%, 0,25%, 0,125% etc., by dilution of the solution twice. A drop of each of the prepared solutions were placed on a glass slide prior to complete drying and the dried surface was carried out confocal scanning microscopy.

Thus, the obtained microcapsules SDA 2 fraction with high yield without special equipment within 10 minutes the Formation of microcapsules occurs spontaneously due to non-covalent vzaimodeistvie, and this says is that, that they are characterized by self-Assembly. Presented on Fig.1-3 structure are ordered, then they have the self-organization. Therefore, encapsulated SDA 2 faction has supramolecular properties.

The method of producing encapsulated particles of antiseptic, stimulant Dorogov (DCA) 2 fraction, characterized in that as the shell is used xanthan gum, which precipitated from solution in butanol in the presence of ester of glycerol with one or two molecules of dietary fatty acids and one or two molecules of citric acid by adding as a precipitator of benzene and drying of the particles is carried out at room temperature.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics and represents an oral pharmaceutical composition for treating intestinal disorders, containing butyric acid or its salt in a combination with water-soluble or water-dispersed dietary fibre specified in inulin, maltodextrin or a mixture thereof, at least one flavouring agent specified in vanillin, vanilla essence or a mixture thereof and one or more pharmacologically acceptable excipients differing by the fact that it contains: a) a matrix containing lipophilic compounds with a melting point of less than 90°C, and an amphiphilic matrix wherein an active ingredient is at least ball-shaped; b) an amphiphilic matrix; c) an outer hydrophilic matrix wherein the lipophilic matrix and the amphiphilic matrix are dispersed; e) a coating; and a portion of the above at least one flavouring agent is dispersed in one or more of the above matrixes, and a portion of the flavouring agent is dispersed in the coating.

EFFECT: preparing the pharmaceutical composition for treating intestinal disorders.

22 cl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a group of inventions involving a pharmaceutical composition, a method of preparing it, a method of treating Parkinson's disease and a method of reducing a 'wear' effect in the given patients by administering the same. The pharmaceutical composition in the form of a single oral dose for treating Parkinson's disease consists of a mixture of a) Levodopa or its salt in an amount of 50 mg to 300 mg in the form of prolonged release, b) Carbidopa or its salt in an amount of 10 mg to 100 mg in the form of prolonged release, wherein the prolonged release is ensured by coating or mixing Levodopa and Carbidopa with one or more rate control polymers, and c) Entacapone or its salt in an amount of 100 mg to 1000 mg in the form of prolonged release, optionally with other pharmaceutically acceptable excipients.

EFFECT: group of inventions promotes patient's treatment compliance; using it leads to a stable blood content of active antigens and to reducing administration rate that provides reducing the 'wear' effect in the patients with Parkinson's disease; besides, the additional technical effect ensured by the composition consists in its stability at high temperature and humidity.

9 cl, 15 tbl

FIELD: medicine.

SUBSTANCE: invention refers to using a polyurethane polymer as a drug delivery system to provide the biologically active risperidone delivery at a constant speed for a relatively long period of time, as well as to methods for using it.

EFFECT: system provides high biological compatibility and biological stability and is applicable as an implant in patients (humans and animals) for the risperidone delivery to tissues and organs.

25 cl, 13 dwg, 3 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: group concerns a prolonged delivery of a compstatin analogue, as well as an optional additional active agent when released from a microscopic gel-like inclusion formed if a liquid composition containing the compstatin analogue is introduced into an extravascular space, such as a vitreous chamber of eye in a mammalian body. The invention also refers to a method of treating an individual suffering age-related macular degeneration (ARMD).

EFFECT: improving the compstatin delivery system for the complement system inhibition required for treating ARMD.

58 cl, 4 ex, 6 tbl, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical compositions containing (2-hydroxyethoxy)amide 6-(4-brom-2-chlorophenylamino)-7-fluor-3-methyl-3H-benzoimidazole-5-carboxylic acid hydrosulphate and solvates, crystalline forms and amorphous forms thereof, to using the above compositions as a drug; and to methods for preparing the above compositions.

EFFECT: preparing the new pharmaceutical compositions.

20 cl, 7 tbl, 7 ex, 5 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a pharmaceutical composition for outpatient treatment and prevention of the cardiovascular diseases, containing therapeutic amounts of a vasodilator, a renin-angiotensin system inhibitor, a thrombocyte aggregation inhibitor, a cholesterol-lowering agent, and an antihypoxic agent. As a vasodilator, the declared composition contains an agent possessing α-adrenergic receptor antagonist action, and a thrombocyte aggregation inhibitor is presented by an ADP-dependent thrombocyte activation mechanism blocking agent.

EFFECT: invention provides the integrated therapeutic effect on the cardiovascular system after acute administration that improves the compliance with treatment regimen by the patient.

20 cl, 1 tbl, 15 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: microparticle contains an agglomerate of particles containing a hydrophilic active substance, wherein the particle contains an amphiphilic polymer composed of a hydrophobic segment of polyhydroxy acid and a hydrophilic segment of polysaccharide or polyethylene glycol, and a hydrophilic active substance. What is also disclosed is a method of producing the agglomerated microparticles, which involves (a) a stage of preparing a reverse phase emulsion, (b) a stage of preparing a solid residue containing the hydrophilic active substance, and (c) a stage of introducing the solid residue into a liquid phase containing a surface modifier.

EFFECT: agglomerated microparticles provide the effective encapsulation of the hydrophilic active substance and the release of the hydrophilic active substance at an appropriate speed.

14 cl, 22 dwg, 4 tbl, 31 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and represents gel-forming mixed dextran esters containing phosphate and carbamate groups of general formula: {C6H7O2(OH)3-x-y{[(OP(O)ONa)mONa)]xl[(O2P(O)ONa)k]x2}x(OCONH2)y}n, wherein x=x1+x2 is a degree of substitution in phosphate groups (mono- and diesters), x=0.47-1.09; X1 is a degree of substitution in monoesters, X1=0.01-0.48; m is a number of phosphates in monoesters, m=1-2; x2 is a degree of substitution in diesters, x2=0.01-1.09; k is a number of phosphates in diesters, k=1-2; y is a degree of substitution in carbamate groups, y=0.39-1.23; n is a degree of polymerisation, 20≥n≤1000.

EFFECT: invention provides producing low-toxic low- and high-substituted dextran phosphates in the form of hydrogels containing additionally carbamate groups and possessing antiproliferative activity with respect to cancer cells.

2 cl, 3 dwg, 14 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmacy and represents microsphere with controlled release, which has covering layer and contains core, which contains exendin as active ingredient and biodegradable polymer, and covering layer, which covers core with covering material, exendin being exendin-4 (SEQ ID NO:2), biodegradable polymer represents polymer, selected from group, consisting of polylactide (PLA), polyglycolide (PGA), lactide and glycolide copolymer (PLGA), polyorthoester, polyanhydride, polyhydroxybutyric acid, polycaprolactone and polyalkylcarbonate; copolymer or simple mixture of two or more polymers, selected from said group of polymers; copolymer of said polymer and polyethylene glycol (PEG); or polymer-sugar complex, in which sugar is bound with said polymer or said copolymer, covering material is selected from group, consisting of essential amino acids, polypeptides and organic nitrogenous compounds, essential amino acid being one or more, selected from group, consisting of arginine, lysine and histidine; polypeptide represents L-Lys-L-Thr-L-Thr-L-Lys-L-Ser; and organic nitrogenous compound is selected from group, consisting of creatine, creatinine and urea, content of covering layer constitutes from 0.01 to 5 wt fractions in terms per 100 wt fractions of microsphere.

EFFECT: invention ensures increase of bioaccessability and reduction of initial peak of exendin for prevention of such side effects as vomiting, nausea, headache.

10 cl, 7 ex, 5 tbl, 7 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: dosage form contains oxycodone hydrochloride as a physiologically active substance (A), optionally one or more physiologically combined excipients (B), a synthetic or natural polymer (C) and optionally natural, semisynthetic or synthetic wax (D).

EFFECT: dosage form of oxycodone hydrochloride possess degradation resistance of at least 400 N to less than 500 N, and releases max 99% of oxycodone hydrochloride in the physiological conditions after 5 h.

14 cl, 7 dwg, 17 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for drug microencapsulation by non-solvent addition; the method is characterised by the fact that the above drugs are presented by cephalosporin preparations, while a coating is human serum albumin precipitated from an aqueous solution by adding methylcarbinol as a non-solvent and acetone at 25°C.

EFFECT: invention provides simplifying and accelerating the microencapsulation process, reducing the microencapsulation loss (higher weight yield).

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for drug encapsulation by non-solvent addition; the method is characterised by the fact that the above drug is presented by fenbendazole, while a coating is sodium carboxymethyl cellulose precipitated from a butanol solution by adding methylcarbinol as a non-solvent and water at 25°C.

EFFECT: invention provides simplifying and accelerating the microencapsulation process, reducing the microencapsulation loss (higher weight yield).

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for drug encapsulation by non-solvent addition; the method is characterised by the fact that the above drug is presented by fenbendazole, while a coating is sodium carboxymethyl cellulose precipitated from a toluene solution by adding butanol as a non-solvent and water at 25°C.

EFFECT: invention provides simplifying and accelerating the microencapsulation process, reducing the microencapsulation loss (higher weight yield).

3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to field of microcapsulation of heterocyclic compounds of triazine series. Method of obtaining microcapsules of triazine series pesticides is characterised by the fact that 0.1 g of triazine series pesticide and 0.02 g of E472c preparation as emulsifying agent are added to 10 g of 5% water solution of polyvinyl alcohol (PVA) and obtained mixture is subjected to mixing. Reaction mixture components are dissolved until transparent solution is formed after which 5 ml of carbinol as the first precipitating agent and then 10 ml of isopropanol as the second precipitating agent are added slowly drop-by-drop. After that, obtained suspension of microcapsules is kept for 1 minute, filtered on filter, washed with propanol several times, dried, with method being realised at 25°C without special equipment.

EFFECT: simplification of the process of obtaining microcapsules and increase output by weight.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for preparing drug microcapsules by nonsolvent addition differing by the fact that the drugs represent the preparations of cephalosporin group, and a coating is poludan deposited from an aqueous solution by adding diethyl ester and isopropanol at 25 °C as a nonsolvent.

EFFECT: invention provides simplifying and accelerating the process of microcapsules, reducing the microcapsule loss (higher weight yield).

3 ex

FIELD: chemistry.

SUBSTANCE: method of obtaining microcapsules of triazine series pesticides is characterised by the following: 0.1 g of triazine series pesticide and 0.02 g of E472c preparation as emulsifier are added to 10 g of 5% water solution of polyvinyl alcohol (PVA), and obtained mixture is subjected to mixing. After dissolution of reaction mixture components and formation of transparent solution 15 ml of isopropanol are very slowly drop-by-drop poured in, and obtained suspension of microcapsules is stayed for 1 minute, filtered on filter, washed several times with isopropanol and dried. Method is realised at 25°C without special equipment.

EFFECT: simplification of the process of obtaining microcapsules and increased output by mass.

3 ex

FIELD: chemistry.

SUBSTANCE: method is characterised by the fact that 100 mg of iron sulphate or zinc sulphate are dissolved in 1 ml of water and obtained mixture is dispersed into carrageenan solution in acetone, which contains 300 mg of carrageenan, in presence of 0.01 g of E472c preparation with mixing. After that, 2 ml of ethanol are added, obtained suspension is filtered and dried at room temperature, with realisation of the method without special equipment.

EFFECT: simplification and acceleration of the process of obtaining microcapsules and increase of output by mass.

2 ex

FIELD: chemistry.

SUBSTANCE: method is characterised by the fact that 100 mg of iron sulphate of zinc sulphate are dissolved in 1 ml of water and obtained mixture is dispersed into solution of kappa-karrageenan in dioxane, which contains 300 mg of kappa-karrageenan, in presence of 0.01 g of E472c preparation with mixing. After that, 2 ml of methylcarbinol are poured in, obtained suspension is filtered and dried at room temperature, with realisation of the method without special equipment.

EFFECT: simplification and acceleration of the process of obtaining microcapsules and increased output by mass.

2 ex

FIELD: chemistry.

SUBSTANCE: invention represents method of encapsulating medication by method of sedimentation with non-solvent, characterised by the fact that as medication used is fenbendazole, as coating - sodium carboxymethylcellulose, which is precipitated from solution in acetone by addition of water as non-solvent at 25°C.

EFFECT: simplification and acceleration of the process of obtaining microcapsules, reduced loss in obtaining microcapsules.

3 ex

FIELD: chemistry.

SUBSTANCE: invention represents method of encapsulating medication by method of sedimentation with non-solvent, characterised by the fact that as medication used is fenbendazole, as coating - sodium carboxymethylcellulose, which is precipitated from solution in acetone by addition of isopropanol as non-solvent and water at 25°C.

EFFECT: simplification and acceleration of the process of obtaining microcapsules, reduced loss in obtaining microcapsules.

3 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes new tablets with size less 3 mm with sustained-releasing the opioid analgesic drug for 30 min in the amount above 75%. Invention provides opioid for oral intake with taking into account individual necessity of patient due to selection of required amount of mictotablets by dispenser.

EFFECT: valuable properties of tablet, expanded assortment of medicinal formulations of opioid analgesics.

19 cl, 4 tbl, 4 ex

Up!